Consideration of disease penetrance in the selection of secondary findings gene-disease pairs: A policy statement of the American College of Medical Genetics and Genomics (ACMG)

ACMG Secondary Findings Working Group

Research output: Contribution to journalArticlepeer-review

2 Scopus citations
Original languageEnglish (US)
Article number101142
JournalGenetics in Medicine
Volume26
Issue number7
DOIs
StatePublished - Jul 2024

Funding

Funding and support listed here did not support development of this document unless included in the acknowledgments section. Noura S. Abul-Husn is an equity holder of 23andMe; serves as a scientific advisory board member for Allelica; received personal fees from Genentech, Allelica, and 23andMe; received research funding from Akcea; and was previously employed by Regeneron Pharmaceuticals. Laura M. Amendola is a shareholder of Illumina, Inc. Wendy K. Chung is a member of the scientific advisory board of Regeneron Genetics Center and on the Board of Directors of Prime Medicine and Rallybio. Douglas R. Stewart is supported by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics of the National Cancer Institute, Rockville, MD and also performs contract clinical telehealth services for Genome Medical, Inc in accordance with relevant NCI ethics policies. All other authors have no conflicts to disclose.

Keywords

  • Exome sequencing
  • Genome sequencing
  • Incidental findings
  • Secondary findings

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this